In today's Pharmaceutical Executive Daily, Rocket Pharmaceuticals announces a $180 million sale of its rare pediatric disease priority review voucher, Teva Pharmaceutical enters a definitive agreement to acquire Emalex Biosciences for up to $900 million, and a feature article examines the pharmaceutical supply chain risks converging around the Strait of Hormuz.
AI Summary coming soon
Sign up to get notified when the full AI-powered summary is ready.
Free forever for up to 3 podcasts. No credit card required.
Pharmaceutical Executive Daily: FDA Approves Auvelity
Pharmaceutical Executive Daily: Sanofi Appoints Belén Garijo as CEO
Pharmaceutical Executive Daily: FDA Approves Breztri
Pharmaceutical Executive Daily: FDA Approves Caplyta for Adults with Schizophrenia
Free AI-powered recaps of Pharmaceutical Executive and your other favorite podcasts, delivered to your inbox.
Free forever for up to 3 podcasts. No credit card required.